Efficacy and safety of vascular intervention combined with intravenous thrombolysis in treatment of acute intracranial arterial occlusion

Zhu,Dawei; Wang,Qunshuan; Zhao,Wenjin; Li,Chengye; Xu,Lixia; Liu,Shunfan

doi:10.3892/etm.2020.9027

Efficacy and safety of vascular intervention combined with intravenous thrombolysis in treatment of acute intracranial arterial occlusion

Authors:
- Dawei Zhu
- Qunshuan Wang
- Wenjin Zhao
- Chengye Li
- Lixia Xu
- Shunfan Liu
View Affiliations

Affiliations: Department of Medical Imaging, People's Hospital of Tongchuan, Tongchuan, Shaanxi 727000, P.R. China, Department of Interventional Radiography, Tongchuan Mining Bureau Central Hospital, Tongchuan, Shaanxi 727000, P.R. China, Department of Interventional Radiography, Ninth Hospital of Xi'an, Xi'an, Shaanxi 710054, P.R. China
Published online on: July 21, 2020 https://doi.org/10.3892/etm.2020.9027
Pages: 2903-2908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Efficacy and safety of vascular intervention combined with intravenous thrombolysis (IVT) was investigated in the treatment of acute intracranial arterial occlusion (AIAO). Ninety‑two patients with AIAO treated in People's Hospital of Tongchuan from January 2014 to February 2016 were enrolled in this retrospective study. Forty‑two patients were treated with vascular intervention (control group), while another 50 patients were treated with vascular intervention combined with IVT (study group). They were observed in terms of the improvement of clinical efficacy after treatment, the comparison of complications after treatment, the National Institute of Health Stroke Scale (NIHSS) score after treatment, the modified Rankin Scale (mRS) score at 3 months after treatment, and the Mini‑Mental State Examination (MMSE) score at 3 months after treatment. Compared with those in the control group, patients in the study group had statistically significantly higher marked effectiveness and statistically significantly lower ineffectiveness (P=0.018), and a statistically significantly higher overall effective rate (P=0.042). The NIHSS score in the study group was statistically significantly lower than that in the control group after treatment (P=0.001). There was a statistically significant difference between the two groups in the mRS score at 3 months after treatment (Z=8.764, P>0.05). Compared with those in the control group, patients in the study group had a statistically significantly higher MMSE score after treatment, and a statistically significantly lower total incidence of postoperative complications (P=0.001). Vascular intervention combined with IVT has good efficacy and high safety in the treatment of AIAO, and the combination can statistically significantly improve patients' quality of life, so it has a good clinical application value.

View Figures

View References

1	Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, Das SR, de Ferranti S, Després JP, Fullerton HJ, et al: Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee: Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 133(e38-e360)2016.PubMed/NCBI View Article : Google Scholar
2	Love S and Miners JS: Cerebrovascular disease in ageing and Alzheimer's disease. Acta Neuropathol. 131:645–658. 2016.PubMed/NCBI View Article : Google Scholar
3	Kamat PK, Vacek JC, Kalani A and Tyagi N: Homocysteine induced cerebrovascular dysfunction: A link to Alzheimer's disease etiology. Open Neurol J. 9:9–14. 2015.PubMed/NCBI View Article : Google Scholar
4	Lahousse L, Tiemeier H, Ikram MA and Brusselle GG: Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 109:1371–1380. 2015.PubMed/NCBI View Article : Google Scholar
5	Drandley TD and Floras JS (eds): Sleep Apnea: Implications in Cardiovascular and Cerebrovascular Disease. CRC Press, Florida. 2016.
6	Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al: American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 49(e46-e110)2018.PubMed/NCBI View Article : Google Scholar
7	Nakamura K, Keating JH and Edelman ER: Pathology of endovascular stents. Interv Cardiol Clin. 5:391–403. 2016.PubMed/NCBI View Article : Google Scholar
8	Rogers C and Edelman ER: Endovascular stent design dictates experimental restenosis and thrombosis. Circulation. 91:2995–3001. 1995.PubMed/NCBI View Article : Google Scholar
9	Ortiz GA and Sacco R: National Institutes of Health Stroke Scale (nihss). Wiley Statistics Reference Online. 2014.PubMed/NCBI View Article : Google Scholar
10	Sulter G, Steen C and De Keyser J: Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke. 30:1538–1541. 1999.PubMed/NCBI View Article : Google Scholar
11	Di Napoli M and Shah IM: Neuroinflammation and cerebrovascular disease in old age: A translational medicine perspective. J Aging Res. 2011(857484)2011.PubMed/NCBI View Article : Google Scholar
12	Modrego PJ, Pina MA and Lerín FJ: The impact of ageing on stroke subtypes, length of stay and mortality: Study in the province of Teruel, Spain. Acta Neurol Scand. 108:435–442. 2003. View Article : Google Scholar
13	Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J and Black S: Stroke Outcome Research Canada (SORCan) Working Group. Stroke outcome in those over 80: A multicenter cohort study across Canada. Stroke. 39:2310–2317. 2008.PubMed/NCBI View Article : Google Scholar
14	Feigin VL: Stroke epidemiology in the developing world. Lancet. 365:2160–2161. 2005.PubMed/NCBI View Article : Google Scholar
15	Feigin V and Hoorn SV: How to study stroke incidence. Lancet. 363:1920–1921. 2004.PubMed/NCBI View Article : Google Scholar
16	DeBaun MR, Armstrong FD, McKinstry RC, Ware RE, Vichinsky E and Kirkham FJ: Silent cerebral infarcts: A review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood. 119:4587–4596. 2012.PubMed/NCBI View Article : Google Scholar
17	Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, et al: Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. Lancet. 384:1929–1935. 2014. View Article : Google Scholar
18	Guillan M, Alonso-Canovas A, Garcia-Caldentey J, Sanchez- Gonzalez V, Hernandez-Medrano I, Defelipe-Mimbrera A, Matute MC, Alonso-Arias MA, Alonso de Leciñana M and Masjuan J: Off-label intravenous thrombolysis in acute stroke. Eur J Neurol. 19:390–394. 2012.PubMed/NCBI View Article : Google Scholar
19	Göthe F, Enache D, Wahlund LO, Winblad B, Crisby M, Lökk J and Aarsland D: Cerebrovascular diseases and depression: Epidemiology, mechanisms and treatment. Panminerva Med. 54:161–170. 2012.PubMed/NCBI
20	Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T and Guillemin F: THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): A randomised controlled trial. Lancet Neurol. 15:1138–1147. 2016.PubMed/NCBI View Article : Google Scholar
21	Goldstein LB, Bertels C and Davis JN: Interrater reliability of the NIH stroke scale. Arch Neurol. 46:660–662. 1989.PubMed/NCBI View Article : Google Scholar